Sinclair
Sinclair is a global medical-aesthetics company whose collagen-stimulator portfolio includes Ellansé and Lanluma. Sinclair is a wholly owned subsidiary of Huadong Medicine Company Limited, but its portfolio role does not make Sinclair the legal or physical manufacturer of every product it commercializes.
Company reference
Section titled “Company reference”| Field | Sinclair |
|---|---|
| Injectable Index relationships | Ellansé and Lanluma |
| Company type | Global medical-aesthetics company |
| Parent company | Huadong Medicine Company Limited |
| Parent listing context | Huadong Medicine is listed in Shenzhen under 000963 |
| Headquarters context | London, United Kingdom |
| Portfolio reach | Sinclair reports availability in more than 55 countries |
Sinclair’s current global site states that it is wholly owned by Huadong Medicine and commercializes products through direct markets and distributor networks (Sinclair 🔗). A Sinclair corporate announcement identifies the company as headquartered in London and Huadong Medicine as the parent (Sinclair corporate announcement 🔗).
Product-role matrix
Section titled “Product-role matrix”| Product | Commercial portfolio | Legal manufacturer | Product form | Approval holder or distributor |
|---|---|---|---|---|
| Ellansé | Sinclair | AQTIS Medical B.V. in the reviewed SSCP | PCL microspheres in a CMC-containing carrier gel | Market-specific |
| Lanluma | Sinclair | Verify from the exact regional IFU | Reconstituted PLLA implant; V and X presentations | Market-specific |
The Ellansé SSCP directly identifies AQTIS Medical B.V. as legal manufacturer (Ellansé SSCP 🔗). Sinclair’s ownership and commercialization of the brand should not overwrite that role.
One company, two different collagen-stimulator architectures
Section titled “One company, two different collagen-stimulator architectures”Sinclair’s presence in two material groups is useful because it shows why company identity does not create product equivalence.
| Brand | Material | Physical form | Preparation |
|---|---|---|---|
| Ellansé | PCL | Microspheres in carrier gel | Ready-to-use implant |
| Lanluma | PLLA | Dry-vial particulate product | Requires presentation-specific preparation |
The products differ in carrier, immediate effect, presentation, preparation, evidence, intended use, and company-role detail.
Parent-company context
Section titled “Parent-company context”Sinclair says it is wholly owned by Huadong Medicine, also known as East China Pharmaceuticals or HMC. Parent ownership can help explain capital, geographic expansion, licensing, and portfolio strategy.
It does not mean:
- Huadong Medicine physically manufactures Ellansé or Lanluma
- Sinclair’s regional subsidiaries hold every approval
- all Huadong aesthetic products belong in the Sinclair portfolio
- shared ownership establishes clinical similarity
Selective timeline
Section titled “Selective timeline”| Date | Event | Why it changes interpretation |
|---|---|---|
| 1971 | Sinclair traces its founding to the United Kingdom | Provides company-history context |
| 2018 | Huadong Medicine acquired Sinclair | Establishes current parent-company relationship |
| 2022 | Sinclair launched a broader global brand transformation | Reflects expansion beyond a narrow injectable portfolio |
| Current | Ellansé and Lanluma remain core injectable brands | Connects Sinclair to PCL and PLLA without merging their product identities |
Sinclair’s current site and privacy materials both describe the 2018 Huadong acquisition (Sinclair global site 🔗; Sinclair privacy policy 🔗).
Source interpretation
Section titled “Source interpretation”Sinclair brand pages are appropriate sources for:
- current portfolio relationships
- public intended-use statements
- IFU and SSCP access
- company contact and adverse-event reporting
- current regional availability notices
They should not be the sole source for comparative superiority, guaranteed duration, or cross-product safety claims.
Related pages
Section titled “Related pages”- European Union regulation records current Lanluma and Ellansé regulatory evidence and manufacturer roles.
- Ellansé separates legal manufacturer, carrier, and current variants.
- Lanluma separates V/X presentations and face/body evidence.
- PCL compares particle-based and solubilized PCL.
- PLLA maps Lanluma to the broader material family.